In a phase 3 study involving 616 patients with unresectable hepatocellular carcinoma, the combination of durvalumab and bevacizumab, alongside transarterial chemoembolisation (TACE), significantly improved median progression-free survival to 15 months compared to 8.2 months with placebo. The hazard ratio for progression-free survival was 0.77, indicating a notable benefit, while safety assessments revealed manageable adverse events. […]

A nomogram was developed to predict early cancer-related death (ecrd) due to recurrence in hepatocellular carcinoma (HCC) patients with BCLC stage B/C. Analysis of 672 patients revealed that the alpha-fetoprotein-tumor burden score, BCLC stage, and AST to ALT ratio were significantly associated with ecrd. The model demonstrated strong predictive efficacy in both training (AUC: 0.754) […]

A new laparoscopic liver resection technique utilizing the ventral avascular area of the inferior vena cava shows promise in improving surgical outcomes. In a study of 256 patients, this method yielded significantly larger tumor resections and reduced intraoperative complications, such as bleeding and tumor compression, compared to traditional approaches. The technique allows for a safer […]

Following neoadjuvant treatment with FOLFIRINOX for pancreatic adenocarcinoma, researchers observed a median overall survival of 177 months for patients achieving complete pathological response (cpr). Among 101 patients studied, overall survival rates after 1, 3, 5, and 10 years were 93%, 75%, 63%, and 51%, respectively. However, one-third experienced disease recurrence, with preoperative chemoradiotherapy correlated to […]

Comprehensive management strategies for hilar cholangiocarcinoma (h-cca) highlight the urgent need for effective treatment options. With the disease often presenting in advanced stages, radical resection remains crucial for prolonging survival. Recent advancements in imaging techniques and the role of immunotherapy offer new avenues for therapy. Additionally, innovations such as novel fiberscopes utilizing near-infrared light enable […]

The development of predictive models for postoperative complications and prognosis significantly aids patients with hepatocellular carcinoma combined with clinically significant portal hypertension (CSHP). Researchers identified key risk factors—including ALBI grade and portal vein occlusion time—and created nomograms demonstrating good predictive performance. These models achieved c-index values of 0.723 for complications, 0.635 for recurrence, and 0.734 […]

A seven-year retrospective study at Weill Cornell revealed that transitioning from laparoscopic to robotic liver surgery significantly improves perioperative outcomes in hepatectomies. Among 353 cases analyzed, robotic hepatectomies demonstrated shorter median lengths of stay by 43% and reduced complication odds by 62% compared to open surgery. The robotic approach also had an 87% lower rate […]

A systematic review and meta-analysis of seven randomized controlled trials, involving 731 patients, confirms that the Enhanced Recovery After Surgery (ERAS) protocol significantly shortens hospital stays by an average of 2.49 days compared to conventional care. Furthermore, it shows potential reductions in hospital costs, readmission rates, and infection incidence. This study marks a pivotal demonstration […]

A multi-institutional study identified key predictors for a “textbook outcome” in liver surgery for intrahepatic cholangiocarcinoma (ICC). The absence of post-hepatectomy liver failure, low intraoperative blood loss, no major infectious complications, and achieving R0 resection were linked to improved overall survival of at least 12 months. Approximately 60.2% of patients achieved these outcomes, significantly enhancing […]